ID18579A - Analog indazol tersubstitusi - Google Patents

Analog indazol tersubstitusi

Info

Publication number
ID18579A
ID18579A IDP972170A ID972170A ID18579A ID 18579 A ID18579 A ID 18579A ID P972170 A IDP972170 A ID P972170A ID 972170 A ID972170 A ID 972170A ID 18579 A ID18579 A ID 18579A
Authority
ID
Indonesia
Prior art keywords
analogue
substituted indazol
indazol
substituted
indazol analogue
Prior art date
Application number
IDP972170A
Other languages
English (en)
Indonesian (id)
Inventor
Anthony Marfat
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ID18579A publication Critical patent/ID18579A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDP972170A 1996-06-25 1997-06-24 Analog indazol tersubstitusi ID18579A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2038596P 1996-06-25 1996-06-25

Publications (1)

Publication Number Publication Date
ID18579A true ID18579A (id) 1998-04-23

Family

ID=21798354

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP972170A ID18579A (id) 1996-06-25 1997-06-24 Analog indazol tersubstitusi

Country Status (43)

Country Link
US (1) US6040329A (pt)
EP (1) EP0912558B1 (pt)
JP (1) JP3152940B2 (pt)
KR (1) KR20000022516A (pt)
CN (1) CN1080260C (pt)
AP (1) AP1025A (pt)
AR (1) AR007456A1 (pt)
AT (1) ATE244713T1 (pt)
AU (1) AU716376B2 (pt)
BG (1) BG64052B1 (pt)
BR (1) BR9712782A (pt)
CA (1) CA2258285C (pt)
CO (1) CO4900056A1 (pt)
CZ (1) CZ423398A3 (pt)
DE (1) DE69723447T2 (pt)
DK (1) DK0912558T3 (pt)
DZ (1) DZ2254A1 (pt)
EA (1) EA002274B1 (pt)
ES (1) ES2201299T3 (pt)
GT (1) GT199700075A (pt)
HK (1) HK1018700A1 (pt)
HN (1) HN1997000079A (pt)
HR (1) HRP970350B1 (pt)
HU (1) HUP9903009A3 (pt)
ID (1) ID18579A (pt)
IL (1) IL127036A (pt)
IS (1) IS4910A (pt)
MA (1) MA24225A1 (pt)
MY (1) MY116915A (pt)
NO (1) NO986103D0 (pt)
NZ (1) NZ332752A (pt)
OA (1) OA10934A (pt)
PA (1) PA8432301A1 (pt)
PL (1) PL330974A1 (pt)
PT (1) PT912558E (pt)
SI (1) SI0912558T1 (pt)
SK (1) SK176598A3 (pt)
TN (1) TNSN97108A1 (pt)
TR (1) TR199802685T2 (pt)
TW (1) TW434237B (pt)
WO (1) WO1997049702A1 (pt)
YU (1) YU60198A (pt)
ZA (1) ZA975581B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934307B1 (en) 1996-06-19 2011-04-27 Aventis Pharma Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
BR9712005A (pt) * 1996-09-04 1999-08-24 Pfizer Derivados de indazol e seus usos como inibidores de fosfodiesterase (pde) tipo IV e produ-Æo do fator de necrose de tumor (tnf)
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
NZ503995A (en) * 1997-11-04 2003-02-28 Pfizer Prod Inc Indazole compounds, and pharmaceutical compositions and uses thereof, based on indazole bioisostere replacement of catechol in PDE4 inhibitors
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
JP2003519139A (ja) * 1999-12-23 2003-06-17 アイコス コーポレイション 環状ａｍｐ−特異的ホスホジエステラーゼ阻害剤
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US6982274B2 (en) * 2001-04-16 2006-01-03 Eisai Co., Ltd. 1H-indazole compound
DK1908463T3 (da) 2001-12-14 2011-11-28 Merck Serono Sa Fremgangsmåder til at inducere ægløsning ved anvendelse af en ikke polypeptid-CAMP-niveaumodulator
CN1688545A (zh) 2002-07-19 2005-10-26 记忆药物公司 磷酸二酯酶4抑制剂,包括n－取代的苯胺及二苯胺类似物
BR0313000A (pt) * 2002-07-19 2005-07-12 Memory Pharm Corp Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente
BR0315705A (pt) * 2002-11-19 2005-09-06 Memory Pharm Corp Inibidores de fosfodiesterase-4
CN1809559B (zh) * 2003-04-18 2010-06-02 记忆药物公司 作为磷酸二酯酶4抑制剂的吡唑衍生物
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
CA2584317A1 (en) 2004-10-15 2006-04-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
WO2006129158A2 (en) * 2005-05-30 2006-12-07 Ranbaxy Laboratories Limited 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1928866A1 (en) * 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN103497185A (zh) 2007-03-14 2014-01-08 兰贝克赛实验室有限公司 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
WO2010003084A2 (en) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011051342A1 (en) * 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
EP3137454A1 (en) 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
KR20220167804A (ko) * 2021-06-11 2022-12-22 주식회사 메타센테라퓨틱스 인돌 유도체를 포함하는 최종당화산물 관련 질환의 치료용 조성물
KR20220167441A (ko) * 2021-06-11 2022-12-21 주식회사 메타센테라퓨틱스 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB753573A (en) * 1953-06-17 1956-07-25 Ici Ltd New dyestuffs intermediates
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
TW223004B (pt) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
MX9301943A (es) * 1992-04-02 1994-08-31 Smithkline Beecham Corp Compuestos.
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
JPH07215952A (ja) * 1993-12-06 1995-08-15 Otsuka Pharmaceut Factory Inc カテコール誘導体
WO1996012720A1 (en) * 1994-10-20 1996-05-02 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines and their use as medicaments

Also Published As

Publication number Publication date
CZ423398A3 (cs) 1999-12-15
SK176598A3 (en) 2000-06-12
DE69723447D1 (de) 2003-08-14
HRP970350A2 (en) 1998-06-30
IS4910A (is) 1998-11-27
ES2201299T3 (es) 2004-03-16
BR9712782A (pt) 1999-12-07
ZA975581B (en) 1998-12-24
KR20000022516A (ko) 2000-04-25
CA2258285A1 (en) 1997-12-31
EA002274B1 (ru) 2002-02-28
EA199801047A1 (ru) 1999-06-24
JP3152940B2 (ja) 2001-04-03
DZ2254A1 (fr) 2002-12-18
TW434237B (en) 2001-05-16
CN1223651A (zh) 1999-07-21
AP9701020A0 (en) 1997-07-31
YU60198A (sh) 1999-09-27
IL127036A0 (en) 1999-09-22
AU2785797A (en) 1998-01-14
PA8432301A1 (es) 1999-12-27
PL330974A1 (en) 1999-06-21
SI0912558T1 (en) 2003-10-31
HK1018700A1 (en) 1999-12-30
TR199802685T2 (xx) 1999-03-22
HRP970350B1 (en) 2003-04-30
MY116915A (en) 2004-04-30
CN1080260C (zh) 2002-03-06
HUP9903009A2 (hu) 2000-05-28
NO986103L (no) 1998-12-23
BG103056A (en) 1999-10-29
CO4900056A1 (es) 2000-03-27
EP0912558A1 (en) 1999-05-06
AR007456A1 (es) 1999-10-27
HUP9903009A3 (en) 2002-01-28
EP0912558B1 (en) 2003-07-09
ATE244713T1 (de) 2003-07-15
CA2258285C (en) 2002-11-26
OA10934A (en) 2002-02-18
TNSN97108A1 (fr) 2005-03-15
DE69723447T2 (de) 2003-12-24
NZ332752A (en) 2001-04-27
AP1025A (en) 2001-11-19
HN1997000079A (es) 1997-12-26
WO1997049702A1 (en) 1997-12-31
AU716376B2 (en) 2000-02-24
PT912558E (pt) 2003-11-28
DK0912558T3 (da) 2003-08-18
US6040329A (en) 2000-03-21
IL127036A (en) 2001-06-14
GT199700075A (es) 1998-12-04
NO986103D0 (no) 1998-12-23
MA24225A1 (fr) 1997-12-31
BG64052B1 (bg) 2003-11-28
JPH11514668A (ja) 1999-12-14

Similar Documents

Publication Publication Date Title
ID18579A (id) Analog indazol tersubstitusi
PT101722A (pt) Formulacoes de analogo de insuluna
DE69636902D1 (de) Lactacystin-analoge
NO983266D0 (no) Distribuert Behandling
ATE255376T1 (de) Schraubbares implantat
ATE242264T1 (de) Heptapeptid oxytocin analogen
DE59606593D1 (de) Analoges stellelement
NO983263L (no) Distribuert behandling
DE59710436D1 (de) Kippvorrichtung
DE59701465D1 (de) Sprühfeuchtwerk
DE59707794D1 (de) Wendestangenanordnung
BR9703379A (pt) Unidade de memória analógica
DE69713349D1 (de) Benutzerprogrammierbarer analogprozessor
KR970703025A (ko) 아날로그 신호 부호기(Analogue signal coder)
BR9602770A (pt) Ataude funebre
KR980003783U (ko) 풀림방지 너트
KR970007809U (ko) 분무기
DE59710718D1 (de) Kippvorrichtung
KR970051013U (ko) 수경렌즈
FI961743A0 (fi) Maetning av blodets sockervaerde ur andningsluft
SE9604449D0 (sv) Capotasto
FI960457A0 (fi) Placering av ovanpao varandra staplade containrar i en jaernvaegsvagn
FI960294A0 (fi) Redskap foer borrning av haol i riktning uppaot
FI964701A0 (fi) Utnyttjande av faerger i datakommunikationsteknik
KR970060869U (ko) 분무장치